等待开盘 08-13 09:30:00 美东时间
+0.040
+0.79%
Urgently (NASDAQ:ULY) reported quarterly losses of $(4.50) per share which missed the analyst consensus estimate of $(1.63) by 176.07 percent. This is a 56.9 percent increase over losses of $(10.44) per share from the
今天 04:07
Companies Reporting Before The Bell • Smithfield Foods (NASDAQ:SFD) is expected...
08-12 16:32
An announcement from Urgent.ly Inc ( ($ULY) ) is now available. On August 5, 20...
08-09 04:40
Urgently Inc. (NASDAQ: ULY) announces the release of its Q2 2025 financial results. A conference call will be held on August 12, 2025, at 5:00 p.m. ET to discuss the results. A press release will precede the call. Participants can join via webcast at investors.geturgently.com or by phone at 1-877-317-6789 (USA) or 1-412-317-6789 (International). The replay will be available on the Investor Relations website. Urgently provides digital roadside and...
08-07 20:36
An announcement from Urgent.ly Inc ( ($ULY) ) is now available. On July 17, 202...
07-24 04:47
BENTON HARBOR, Mich., July 21, 2025 /PRNewswire/ -- Whirlpool Corporation (NYSE: WHR) will release its second-quarter financial results and presentation materials at 4:05 p.m. ET on Monday, ...
07-22 04:05
Finnair Oyj press release (OTCPK:FNNNF): Q2 GAAP EPS of €0.06. Revenue of €787.7M (+2.8% Y/Y). OUTLOOK AND GUIDANCE ON 16 JULY 2025: Global air traffic is expected to continue growing in 2025. However...
07-16 15:11
Chardan Capital analyst James McIlree maintains Urgently (NASDAQ:ULY) with a Buy and maintains $15 price target.
07-14 20:10
Urgent.ly Inc ( ($ULY) ) just unveiled an announcement. On July 11, 2025, Urgen...
07-12 05:18
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1147088025548091392.png</p><span style="color:#999999;">编者按:每日追踪华尔街最新评级与目标价,挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Leerink Partners:维持再鼎医药(ZLAB)"跑赢大市"评级,目标价从73美元升至75美元</p> <p>• 美银证券:维持BioCryst Pharma(BCRX)"买入"评级,目标价从13美元升至15美元
07-02 09:54